ClinicalTrials.gg
Active, not recruitingNCT05869955Updated Aug 3, 2026

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

A Phase 1 interventional study of CC-97540 and Fludarabine in Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy and Systemic Sclerosis, sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company. Active, not recruiting at 46 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
270
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb — 5 open to participants now, 9 under way, 3 of them phase 3. Lupus Erythematosus, Systemic · Bristol-Myers Squibb.

Planned enrollment
7th of 19
270 · median 125
Started
2023
with 3 others
Phase 1
7 of 20
2 open now
Registered
13th of 20
by date

Among the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, this one is the 7th largest by planned enrollment of the 19 interventional ones that give a count, is one of 4 that started in 2023, is one of 7 in phase 1, and was the 13th registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

5 of the 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lupus Erythematosus, Systemic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory autoimmune diseases (Breakfree-1).

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Idiopathic Inflammatory Myopathy
  • Systemic Sclerosis
  • Rheumatoid Arthritis

Keywords

  • CC-97540
  • BMS-986353
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Diagnosis of Systemic Lupus Erythematosus (SLE) defined as follows:.

i) Fulfilling the 2019 European League Against Rheumatism (EULAR) / American College of Rheumatology (ACR) classification criteria of SLE.

ii) Presence of anti-dsDNA, anti-histone, anti-chromatin, anti-Ro (anti-SS-A), anti-La (anti-SS-B), or anti-Sm antibodies at screening.

- SLE disease activity:.

i) Active disease at screening, with recent ≥ 1 major organ system with a BILAG A score (excluding musculoskeletal, mucocutaneous, and/or constitutional organ system).

ii) Inadequate response to and to at least 2 of the following treatments, used for at least 3 months each: cyclophosphamide, mycophenolic acid or its derivatives, belimumab, azathioprine, anifrolumab, methotrexate, rituximab, obinutuzumab, cyclosporin, tacrolimus or voclosporin.

  • Diagnosis of Idiopathic Inflammatory Myopathy (IIM) defined as follows:.

    i) Fulfilling the 2017 EULAR/ACR classification criteria for probable or definite IIM.

ii) Participant diagnosed with the following IIM subgroups: dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and polymyositis (PM).

iii) Presence of at least 1 myositis specific antibody (MSA), associated antibody (MAA), or ANA at screening or prior to screening.

  • IIM disease activity:.

    i) Severe/moderate muscle AND/OR skin involvement.

ii) Proof of activity as documented by:.

A. An active myositis-associated rash OR.

B. A recent muscle OR.

C. An elevated CK > 3 times the OR.

D. Participants diagnosed IIM AND progressive Interstitial Lung Disease (ILD) on high-resolution computed tomography (HRCT)

iii) Inadequate response to glucocorticoids and at least 2 of the following treatments used for at least 3 months: azathioprine, methotrexate, cyclosporin A, tacrolimus, MMF, cyclophosphamide, IVIG, JAK inhibitors, and rituximab.

  • Diagnosis of Systemic Sclerosis (SSc) defined as follows:.

    i) Fulfilling 2013 EULAR/ACR classification criteria for SSc.

ii) Antinuclear Antibody (ANA) positive at screening or prior to screening.

- SSc disease activity:.

i) Participants diagnosed with diffuse cutaneous SSc OR diffuse or limited cutaneous SSc AND progressive ILD, AND.

ii) Inadequate response to at least 1 of the following treatments used for at least 3 months: mycophenolate, cyclophosphamide, rituximab, nintedanib, azathioprine, tocilizumab, or intravenous immunoglobulins (IVIG).

- Rheumatoid Arthritis (RA) disease activity:.

i) Minimum of 3 SJC and 3 TJC on a 66/68 joint count (SJC/TJC).

ii) OR participants diagnosed with progressive ILD (interstitial lung disease).

iii) AND Inadequate disease response or intolerance to at least one conventional synthetic disease-modifying antirheumatic drug (DMARD) and as well as ≥ 2 DMARDs with different mechanisms of action from the categories biologic disease-modifying antirheumatic drug (bDMARDs) or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) for a minimum of 3 months.

A. Participants qualifying on progressive ILD may have exhausted the therapies above OR have demonstrated inadequate disease response or intolerance to at least one of the following treatments used for at least 3 months: mycophenolate, tocilizumab, cyclophosphamide, rituximab, azathioprine, nintedinib, pirfenidone.

Exclusion criteria

Exclusion Criteria

- Diagnosis of drug-induced SLE rather than idiopathic SLE.

- Other systemic diseases (eg, multiple sclerosis, psoriasis, inflammatory bowel disease, etc) are excluded. Participants with type I autoimmune diabetes mellitus, thyroid autoimmune disease, Celiac disease, or secondary Sjögren's syndrome are not excluded.

  • SLE overlap syndromes including, but not limited to, rheumatoid arthritis, scleroderma, and mixed connective tissue disease, are excluded.
  • Present or recent CNS pathology, within 12 months.
  • IIM disease activity:.

    i) Other forms of IIM: Inclusion Body Myositis, Amyopathic DM, any form of juvenile myositis.

ii) Myositis other than IIM, eg, drug-induced myositis and PM associated with .

iii) Participants with severe muscle damage (Physician VAS for muscle damage in Myositis Damage Index > 7 cm on a 10 cm scale), permanent weakness due to a non-IIM cause (eg, stroke), or myositis with cardiac involvement.

- SSc disease activity:.

i) SSc related PAH requiring active treatment.

ii) Rapidly progressive SSc related lower GI (small and large intestines) involvement (requiring parenteral nutrition); active gastric antral vascular ectasia.

iii) Prior scleroderma renal crisis.

- RA disease activity:.

i) Prior history of or current inflammatory joint disease other than RA.

ii) Joint damage and/or deformity that may confound the investigator's ability to accurately assess disease activity.

- Other protocol-defined Inclusion/Exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
270 participants (estimated)

Study arms

  • Experimental
    Administration of CC-97540

    Drug: CC-97540 · Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Tocilizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of participants with treatment-emergent adverse events (AEs) in each indication.

    Time frame: Up to 2 years after CC-97540 infusion

  2. Number of participants with serious AEs (SAEs) in each indication.

    Time frame: Up to 2 years after CC-97540 infusion

  3. Number of participants with AEs of special interest (AESI) in each indication.

    Time frame: Up to 2 years after CC-97540 infusion

  4. Number of participants with laboratory abnormalities in each indication.

    Time frame: Up to 2 years after CC-97540 infusion

  5. Number of participants with Dose Limiting Toxicities (DLT) in each indication.

    Time frame: Up to 2 years after CC-97540 infusion

  6. Recommended Phase 2 Dose (RP2D) of CC-97540 in each indication.

    Time frame: Up to 2 years after CC-97540 infusion

Secondary outcomes

  1. Proportion of participants achieving definition of remission in SLE (DORIS) remission

    SLE Cohort

    Time frame: At week 24

  2. Proportion of participants achieving Lupus Low Disease Activity State (LLDAS)

    SLE Cohort

    Time frame: At week 24

  3. Change in proteinuria measured by urine protein creatinine ratio (UPCR)

    SLE Cohort

    Time frame: At week 24

  4. Change in Health Assessment Questionnaire - Disability Index (HAQ-DI)

    Time frame: At week 24

  5. Proportion of participants achieving Myositis Response Criteria (MRC) Total Improvement Score (TIS) Major Response

    IIM Cohort

    Time frame: At Week 24

  6. Change in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)

    Only Dermatomyositis (DM) participants in the IIM Cohort

    Time frame: At Week 24

  7. Proportion of participants with ILD with no worsening of pulmonary function including forced expiratory volume (FEV1) (> 10%), forced vital capacity (FVC) (> 10%), and diffusing capacity of the lung for carbon monoxide (DLCO) (> 15%)

    IIM Cohort

    Time frame: At Week 24

  8. Proportion of participants achieving a minimal clinically important difference (MCID) of 24% change from baseline of the modified Rodnan Skin Score (mRSS)

    SSc Cohort

    Time frame: At Week 24

  9. Participants with an improvement from baseline of the Revised Composite Response Index in Systemic Sclerosis (CRISS)

    SSc Cohort

    Time frame: At Week 24

  10. The worsening of pulmonary function including FVC (>10% absolute), DLCO (>15% absolute decline) in participants with interstitial lung disease (ILD)

    SSc Cohort

    Time frame: At Week 24

  11. Proportion of participants achieving low Disease Activity Score-28 Joint C-Reactive Protein (DAS28-CRP)

    RA cohort

    Time frame: At week 24

  12. Proportion of participants achieving simplified disease activity index (SDAI) remission

    RA cohort

    Time frame: At week 24

  13. Proportion of participants with ILD with no worsening of pulmonary function including FVC (> 10%)

    RA cohort

    Time frame: At week 24

  14. Maximum observed blood concentration (Cmax)

    Time frame: Up to 2 years

  15. Time of maximum observed blood concentration (Tmax)

    Time frame: Up to 2 years

  16. Area under the blood concentration-time curve from time zero to 28 days after dosing (AUC(0-28D))

    Time frame: Up to 2 years

07

Study locations

46 sites
  • Local Institution - 0035
    Aurora, Colorado 80045, United States
  • Local Institution - 0024
    Denver, Colorado 80218, United States
  • Local Institution - 0006
    Jacksonville, Florida 32224, United States
  • Local Institution - 0056
    Miami, Florida 33136, United States
  • Local Institution - 0053
    Chicago, Illinois 60612, United States
  • Local Institution - 0038
    Boston, Massachusetts 02115, United States
  • Local Institution - 0033
    Worcester, Massachusetts 01655, United States
  • University of Massachusetts Chan Medical School
    Worcester, Massachusetts 01655, United States
  • Local Institution - 0031
    Ann Arbor, Michigan 48109-2800, United States
  • Local Institution - 0037
    Detroit, Michigan 48202, United States
  • Local Institution - 0022
    Rochester, Minnesota 55905, United States
  • Local Institution - 0010
    St Louis, Missouri 63110, United States
  • Local Institution - 0028
    Omaha, Nebraska 68198, United States
  • Local Institution - 0008
    Summit, New Jersey 07901, United States
  • Local Institution - 0002
    New York, New York 10016, United States
  • Local Institution - 0011
    New York, New York 10029, United States
  • Local Institution - 0007
    New York, New York 10032, United States
  • Local Institution - 0003
    Chapel Hill, North Carolina 27599, United States
  • Local Institution - 0005
    Cleveland, Ohio 44195, United States
  • Local Institution - 0036
    Dallas, Texas 75390, United States
  • Local Institution - 0029
    Houston, Texas 77030, United States
  • Local Institution - 0034
    Houston, Texas 77030, United States
  • Local Institution - 0004
    Seattle, Washington 98104, United States
  • Local Institution - 0057
    Seattle, Washington 98105, United States
  • Local Institution - 0058
    Seattle, Washington 98109, United States
  • Local Institution - 0019
    Leuven, Vlaams-Brabant 3000, Belgium
  • Local Institution - 0044
    Pessac, Aquitaine 33600, France
  • Local Institution - 0015
    Montpellier, Hérault 34295, France
  • Local Institution - 0016
    Lille, 59037, France
  • Local Institution - 0040
    Nice, 06202, France
  • Local Institution - 0018
    Paris, 75010, France
  • Local Institution - 0020
    Rennes, 35033, France
  • Local Institution - 0049
    Würzburg, Bavaria 97080, Germany
  • Local Institution - 0042
    Cologne, North Rhine-Westphalia 50937, Germany
  • Local Institution - 0041
    Leipzig, Saxony 04103, Germany
  • Local Institution - 0045
    Magdeburg, Saxony-Anhalt 39120, Germany
  • Local Institution - 0025
    Berlin, 10117, Germany
  • Local Institution - 0047
    Düsseldorf, 40225, Germany
  • Local Institution - 0017
    Erlangen, 91054, Germany
  • Local Institution - 0012
    Rome, Lazio 00168, Italy
  • Local Institution - 0023
    Rozzano, Milano 20089, Italy
  • Local Institution - 0014
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Local Institution - 0013
    Santander, Cantabria 39008, Spain
  • Local Institution - 0021
    Barcelona, Catalunya [Cataluña] 08036, Spain
  • Local Institution - 0050
    Córdoba, 14004, Spain
  • Local Institution - 0039
    Málaga, 29011, Spain
08

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Aug 2028, 59 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 59 months is above that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2023
First posted
May 23, 2023
StartActual
Sep 13, 2023
Primary completionEst.
Aug 29, 2028
CompletionEst.
Aug 29, 2028
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05869955
Collaborators
Bristol-Myers Squibb Services Unlimited Company
Responsible party
Sponsor
First posted
May 23, 2023
Start date
Sep 13, 2023
Primary completion
Aug 29, 2028 (estimated)
Completion
Aug 29, 2028 (estimated)
Last update
Aug 3, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolacabtagene autoleucel

Start the discussion